United States

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

24 Mar 2017
Change (% chg)

¥-0.06 (-0.11%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for 600276.SS


JIANGSU HENGRUI MEDICINE CO., LTD. is principally engaged in the manufacturing and distribution of pharmaceutical tablets, injections and raw materials. The Company’s main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, drugs for the treatment of endocrine, antibiotics, infusions... (more)


Beta: 0.47
Market Cap(Mil.): ¥125,542.10
Shares Outstanding(Mil.): 2,347.46
Dividend: 0.14
Yield (%): 0.16


  600276.SS Industry Sector
P/E (TTM): 48.41 29.17 29.94
EPS (TTM): 1.10 -- --
ROI: 23.42 13.48 13.01
ROE: 23.20 14.39 14.16

BRIEF-Jiangsu Hengrui Medicine receives new drug license

* Says the co received new drug license for Caspofungin Acetate for Injection, getting approval to sell it in UK and Germany

Mar 16 2017

BRIEF-Jiangsu Hengrui Medicine announces FY 2016 dividend payment

* Says it plans to use undistributed profits to pay a cash dividend of 1.35 yuan (pre-tax) per 10 shares to shareholders for FY 2016

Mar 13 2017

BRIEF-Jiangsu Hengrui Medicine's 2016 net profit up 19.2 pct

* Says its 2016 net profit up 19.2 percent y/y at 2.6 billion yuan ($376.08 million)

Mar 10 2017

BRIEF-Jiangsu Hengrui Medicine and unit get approval for drug clinical trial

* Says the co and its unit received approval from China Food and Drug Administration to start new drug SHR-1309 injection clinical trial

Mar 10 2017

BRIEF-Jiangsu Hengrui Medicine passes FDA approval

* Says co received approval for its Cisatracurium Besylate injection from U.S Food and Drug Administration

Feb 07 2017

BRIEF-Jiangsu Hengrui Medicine and unit commence phase I clinical trial for SHR-1314

* Says the co and its unit commenced phase I clinical trial for injection SHR-1314

Nov 17 2016

BRIEF-Jiangsu Hengrui Medicine gets nod for clinic trial

* Says it and its unit get China Food and Drug Administration's approval for a nasal spray and a tablet' s clinic trial

Nov 07 2016

BRIEF-Jiangsu Hengrui Medicine's 9-month net profit up 22.7 pct

Further company coverage: (Reporting by Hong Kong newsroom)

Oct 28 2016

More From Around the Web

Earnings vs. Estimates